Stockscreener 앱 받기
2.03
1.17%
-0.024
시간 외 거래:
2.03
전일 마감가:
$2.054
열려 있는:
$2.1
하루 거래량:
249.28K
Relative Volume:
1.21
시가총액:
$35.52M
수익:
-
순이익/손실:
$-30.15M
주가수익비율:
-0.5075
EPS:
-4
순현금흐름:
$-21.66M
1주 성능:
-3.33%
1개월 성능:
+13.41%
6개월 성능:
+59.84%
1년 성능:
-3.33%
1일 변동 폭
$2.01
$2.14
1주일 범위
$1.97
$2.14
52주 변동 폭
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
명칭
Nrx Pharmaceuticals Inc
전화
484-254-6134
주소
1201 ORANGE STREET, WILMINGTON
NRXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.03 | 35.52M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | BTIG Research | Buy |
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation - TipRanks
NRx Pharmaceuticals seeks patent for preservative-free ketamine - Investing.com
NRXP's Groundbreaking Ketamine Patent Could Secure 20-Year Market Exclusivity for Depression Treatment - Stock Titan
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
FDA Filing Fee Waiver for New Drug Application of NRX-100 for Suicidal Depression - Psychiatric Times
$4.3 Million Waiver Exemption Granted by FDA on New Drug - openPR.com
$4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Promising Treatment Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
Wheat Sees Some Bargain Buying at Month End - The Globe and Mail
Neuroscience and Psychiatry: Mending the Schism - Psychiatric Times
FDA Awards NRx Pharmaceuticals $4.3M Waiver for Revolutionary Suicidal Depression Treatment - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
X Marks the Spot: Challenges for Therapeutic Target Engagement in DBS - Psychiatric Times
Deep Brain Stimulation: A Pacemaker for the Brain - Psychiatric Times
Easy Steps to Help Reduce Physician Suicide - Psychiatric Times
Physicians as Humans First: Helping Prevent Physician Suicide - Psychiatric Times
NRx Pharmaceuticals CEO Sets to Reveal Growth Strategy at Exclusive H.C. Wainwright Discussion - Stock Titan
"You Need to Help Yourself Before Helping Patients": Reducing Physician Suicide - Psychiatric Times
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics (PR Newswire) - Aktiellt
The Female Physician Suicide Risk: 53% Higher Than Women in the General Population - Psychiatric Times
NRx Pharmaceuticals increases at-the-market offering to $20M - Investing.com Australia
NRx Pharmaceuticals increases at-the-market offering to $20M By Investing.com - Investing.com Canada
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
60 Degrees Pharma signs patent agreement with Yale for tick disease medicine development - Mugglehead Magazine
HOPE Therapeutics secures $2.5 million investment By Investing.com - Investing.com South Africa
Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD with Groundbreaking Drugs and Modalities: $NRXP - The Globe and Mail
Hope Therapeutics And Nrx Pharma Announce Signing Of A Term Sheet For Strategic Investment From A Global Medical Device Manufacturer - MarketScreener
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE - Morningstar
BTIG Initiates Coverage of NRx Pharmaceuticals (NRXP) with Buy Recommendation - Nasdaq
BTIG initiates NRx Pharmaceuticals with $18 price target By Investing.com - Investing.com Australia
BTIG initiates NRx Pharmaceuticals with $18 price target - Investing.com
Reset the Clock on Schizophrenia: SPG302, A Regenerative Treatment - Psychiatric Times
LB-102: A New, Novel Drug for Schizophrenia - Psychiatric Times
HOPE Therapeutics expands with Dura Medical acquisition By Investing.com - Investing.com Canada
NRx Pharmaceuticals' Hope Therapeutics to acquire Dura Medical, no terms - MSN
NRx Pharma: HOPE Therapeutics Signs Deal To Buy Dura Medical - Nasdaq
HOPE Therapeutics expands with Dura Medical acquisition - Investing.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics - Longview News-Journal
Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now - MSN
Exciting Agents in the 2025 Mood Disorders Treatment Pipeline - Psychiatric Times
HOPE Therapeutics set to acquire majority of Neurospa By Investing.com - Investing.com Australia
$300 Million in Milestones; Double-Digit Royalties; LOI with - openPR.com
NRx Pharmaceuticals Unit Signs Letter of Intent to Acquire Neurospa TMS -March 24, 2025 at 08:43 am EDT - MarketScreener
HOPE Therapeutics and NRx Pharmaceuticals Sign Binding Letter of Intent with Neurospa TMS Holdings - MarketScreener
HOPE Therapeutics set to acquire majority of Neurospa - Investing.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics - Longview News-Journal
NRX Pharmaceuticals Reports 2024 Financial Results and Strategy - TipRanks
Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2024 Earnings Call Transcript - Insider Monkey
Nrx Pharmaceuticals Inc (NRXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):